Quest Diagnostics Incorporated (DGX) Revenue by Segment

Quest Diagnostics revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Quest Diagnostics's largest business segment was Diagnostic Information Services Business, with $2.98 billion or 98% of revenue, up 10.3% from a year earlier. Next: All other segments (2%).

By product or service, Routine clinical testing and other services brought in 45%, Gene-based and esoteric testing services brought in 34% and COVID-19 Testing Services brought in 13% of revenue in Q3 fiscal 2022.

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Quest Diagnostics Incorporated

DGXHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Diagnostic Information Services BusinessAll other segmentsOther Operating

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before	Trend
Diagnostic Information Services Business	USD 2.98B	97.9%	+10.3%
All other segments	USD 65.00M	2.1%	+4.8%

Sum of items USD 3.04B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Diagnostic Information Services Business	3.0B	2.8B	2.7B	2.8B	2.7B	2.6B	2.6B	2.4B	2.3B	2.3B	2.2B	2.2B	2.3B	2.3B	2.3B	2.4B	2.4B	2.5B	2.7B	2.7B	2.5B	2.6B	2.9B	2.7B	1.8B	1.7B	1.8B	1.9B	1.9B	1.8B	1.8B	1.8B	1.8B	1.8B	–	1.8B
All other segments	65.0M	63.0M	64.0M	61.0M	62.0M	63.0M	65.0M	61.0M	64.0M	68.0M	67.0M	67.0M	70.0M	72.0M	68.0M	67.0M	69.0M	70.0M	70.0M	71.0M	76.0M	77.0M	80.0M	77.0M	63.0M	78.0M	82.0M	79.0M	81.0M	79.0M	83.0M	–	–	–	–	–
Other Operating	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	79.0M	84.0M	81.0M	–	79.0M

Quest Diagnostics revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Diagnostic Information Services Business	$3.0B	$2.8B	$2.8B	$2.7B	98%
All other segments	$65.0M	$63.0M	$61.0M	$62.0M	2%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Quest Diagnostics revenue by product or service, last 4 quarters

Product or service	Q3 FY22	Q2 FY22	Q1 FY22	Q3 FY21	Share
Routine clinical testing and other services	$1.1B	$1.1B	$1.1B	$1.2B	45%
Gene-based and esoteric testing services	$835.0M	$787.0M	$739.0M	$646.0M	34%
COVID-19 Testing Services	$316.0M	$355.0M	$599.0M	$709.0M	13%
Anatomic pathology testing services	$149.0M	$144.0M	$137.0M	$138.0M	6%
All other services	$67.0M	$69.0M	$70.0M	$71.0M	3%

In USD, fiscal quarters as reported; share = part of Q3 FY22 revenue.

Questions and answers

What are Quest Diagnostics's business segments?

Diagnostic Information Services Business and All other segments (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Quest Diagnostics?

Diagnostic Information Services Business: $2.98 billion, or 98% of revenue, in Q2 fiscal 2026.

What are Quest Diagnostics's main products and services?

By revenue in Q3 fiscal 2022: Routine clinical testing and other services (45%), Gene-based and esoteric testing services (34%), COVID-19 Testing Services (13%) and Anatomic pathology testing services (6%).

MoreQuest Diagnostics stock overview Quest Diagnostics financials Quest Diagnostics executive team Quest Diagnostics shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.